ABM Therapeutics
PrivateLast Round
Series B
Extension
May 4, 2023
Total Funding Raised
$50M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
ABM Therapeutics is a clinical-stage biopharmaceutical company that develops small molecule targeted therapies for the treatment of brain cancer and cancer metastases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ABM Therapeutics Comparables
Compare ABM Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Black Diamond Therapeutics | 78% | |
| Servier | 76% | |
| Suzhou NeuPharma Co., Ltd. | 75% |
ABM Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | May 4, 2023 | ||||
| Series B | Jan 4, 2022 | ||||
| Series A | Aug 7, 2020 |
ABM Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| HighLight Capital | Series B |
| Photon Fund | Series B |
| Sincere Capital | Series B |
| Jiangsu Honghui Equity Investment Management | Series B |
| Kaitai Capital | Series A |
| 健壹资本 | Series A |
| Baidu Ventures | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 12, 2026
Monthly visitors grew 65% MoM, from 307 to 507.
- Jan 4, 2022
$30M round led by Photon Fund and HighLight Capital
ABM Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about ABM Therapeutics's valuation, stock price, and market status.
Is ABM Therapeutics a public or private company?
ABM Therapeutics is a private company.
What is the current stock price of ABM Therapeutics?
ABM Therapeutics is a private company, so its shares have no public market price. Caplight tracks ABM Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ABM Therapeutics worth (valuation)?
Valuation information for ABM Therapeutics is not publicly available.
Can I buy ABM Therapeutics stock?
ABM Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ABM Therapeutics's last funding round?
ABM Therapeutics's most recent funding round was Series B Extension on May 4, 2023.
Who are the main investors in ABM Therapeutics?
Key investors in ABM Therapeutics include HighLight Capital, Photon Fund, China Growth Capital, 华创资本.
Will ABM Therapeutics IPO soon?
No public IPO plans have been announced for ABM Therapeutics.
How can I track ABM Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in ABM Therapeutics's shares on secondary markets.